YWYan Wang

Yan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yan Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Chen Zhang

    School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

    1 shared publication
  • Fei Gao

    State Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, China

    1 shared publication
  • Jianping Chen

    School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China

    1 shared publication
  • Jinming Zhang

    Chengdu University of Traditional Chinese Medicine

    1 shared publication
  • Kumar Ganesan

    School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China

    1 shared publication
  • Peng Li

    Macau Centre for Research and Development in Chinese Medicine, State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, 999078, Macao Special Administrative Region of China

    1 shared publication

Latest Publications

  • Open Access

    Targeting Engineered Nanoparticles for Breast Cancer Therapy

    by Kumar Ganesan, Yan Wang, Fei Gao, Qingqing Liu, Chen Zhang, Peng Li, Jinming Zhang, Jianping Chen

    Breast cancer (BC) is the second most common cancer in women globally after lung cancer. Presently, the most important approach for BC treatment consists of surgery, followed by radiotherapy and chemotherapy. The latter therapeutic methods are often unsuccessful in the treatment of BC because of their various side effects and the damage incurred to healthy tissues and organs. Currently, numerous nanoparticles (NPs) have been identified and synthesized to selectively target BC cells without causing any impairments to the adjacent normal tissues or organs. Based on an exploratory study, this comprehensive review aims to provide information on engineered NPs and their payloads as promising tools in the treatment of BC. Therapeutic drugs or natural bioactive compounds generally incorporate engineered NPs of ideal sizes and shapes to enhance their solubility, circulatory half-life, and biodistribution, while reducing their side effects and immunogenicity. Furthermore, ligands such as peptides, antibodies, and nucleic acids on the surface of NPs precisely target BC cells. Studies on the synthesis of engineered NPs and their impact on BC were obtained from PubMed, Science Direct, and Google Scholar. This review provides insights on the importance of engineered NPs and their methodology for validation as a next-generation platform with preventive and therapeutic effects against BC.